AirasL. Exposure to natalizumab during pregnancy and lactation is safe – No. Mult Scler2020; 26(8): 889–891.
2.
LandiDMarfiaGA. Exposure to natalizumab during pregnancy and lactation is safe – Yes. Mult Scler2020, 26(8): 887–889.
3.
HyrichKLVerstappenSM.Biologic therapies and pregnancy: The story so far. Rheumatology2014; 53(8): 1377–1385.
4.
LevyRAde JesúsGRde JesúsNR, et al. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev2016; 15(10): 955–963.
5.
PuchnerAGrochenigHPSautnerJ, et al. Immunosuppressives and biologics during pregnancy and lactation: A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr2019; 131(1–2): 29–44.
6.
MahadevanURobinsonCBernaskoN, et al. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology2019; 156: 1508–1524.
7.
FriendSRichmanSBloomgrenG, et al. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: A global, observational, follow-up study. BMC Neurol2016; 16: 150.
8.
PortaccioEAnnovazziPGhezziA, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology2018; 90: e823–e831.
9.
HaghikiaALanger-GouldARellensmannG, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol2014; 71: 891–895.
10.
CipleaAILanger-GouldAde VriesA, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm2020; 7: e723.
11.
BakerTECooperSDKesslerL, et al. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact2015; 31(2): 233–236.
12.
GiragossianCClarkTPiche-NicholasN, et al. Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. Curr Drug Metab2013; 14(7): 764–790.
